Episode 947
Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS – Featuring Drs Wickersham, Winthrop, and Ritchlin Sponsored by AbbVie Medical Affairs
September 30, 202224m 17s
Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.